Sports / Entertainment

China Kangtai Cactus Biotech To Announce 2010 Financial Results on March 31
China Kangtai Cactus Biotech Inc. , a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based products in China, announced today that it plans to announce its fully audited 2010 financial results on March 31, 2011.

Read more on Business Wire via Yahoo! Finance

Marcadia Biotech principals ponder next course
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.

Read more on Indianapolis Business Journal

Emerging Biotech Company Athera and Lonza Sign Development and Manufacturing Agreement
BASEL, SWITZERLAND–(Marketwire – March 17, 2011) -

Read more on Marketwire

Marina Biotech Announces First Patient Enrollment in Familial Adenomatous Polyposis Clinical Trial
CEQ508 Is the First Oral RNAi-Based Therapeutic to Enter Human Clinical Studies

Read more on Marketwire

Wolf Greenfield Names Technology Specialist and Patent Agent; DiPietrantonio, Ph.D., Specializes in Biotech Patents …
BOSTON, MA–(Marketwire – March 15, 2011) – Heather J. DiPietrantonio, Ph.D., recently joined Wolf, Greenfield & Sacks, P.C., a Boston intellectual property law firm, as a patent agent, and Daniel G. Rudoy, Ph.D., joined as a technology specialist.

Read more on Marketwire

Lawmakers tell Scripps to show them jobs that justify state’s investment in its biotech research
Lawmakers tell Scripps to show them jobs that justify state’s investment in its biotech research

Read more on The Palm Beach Post

Biotech sector to see uptick in M&As: Grant Thornton
The biotechnology industry in India is likely to see a significant uptick in the merger and acquisition (M&A) activity, primarily on the back of drastic restructuring that companies from the West had to undergo post the economic recession. However, challenges such as funding constraints may continue to persist, even as the Asian biotech economy would maintain growth with focus on research …

Read more on Business Standard India

NSF International acquires biotech & pharma lab company
Incorporated into the parent company’s Health Sciences Division, NSF Pharmalytica will operate mainly as a contract laboratory focusing on Good Laboratory Practice (GLP) and Good Manufacturing Practises (GMP).

Read more on Nutraingredients.com

Genzyme: Sanofi-Aventis to buy U.S. biotech company for $20.1B
Sanofi-Aventis is buying specialty drugmaker Genzyme for $20.1 billion, the latest example of a beleaguered pharmaceutical company snapping up high-priced biotech drugs to offset dwindling sales of older, simpler medications facing generic competition.

Read more on Inside Bay Area

US biotech firm Genzyme valued at $20.1 bln in sweetened all-cash takeover by Sanofi-Aventis
PARIS – French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market in lucrative drugs for rare genetic disorders.

Read more on Minneapolis-St. Paul Star Tribune